Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C12H22O11 |
| Molecular Weight | 342.297 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)([C@H](O)CO)[C@H](O)C(=O)CO
InChI
InChIKey=PFCRQPBOOFTZGQ-VZXVHDRGSA-N
InChI=1S/C12H22O11/c13-1-4(16)7(18)11(5(17)2-14)23-12-10(21)9(20)8(19)6(3-15)22-12/h5-15,17-21H,1-3H2/t5-,6-,7-,8+,9+,10-,11-,12+/m1/s1
| Molecular Formula | C12H22O11 |
| Molecular Weight | 342.297 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugs.com/mtm/lactulose.html
Sources: https://www.drugs.com/mtm/lactulose.html
Lactulose is a non-absorbable sugar used in the treatment of constipation and hepatic encephalopathy. It is a disaccharide (double-sugar) formed from one molecule each of the simple sugars (monosaccharides) fructose and galactose. Lactulose is not normally present in raw milk but is a product of heat-processed: the greater the heat, the greater amount of this substance. Lactulose is not absorbed in the small intestine nor broken down by human enzymes, thus stays in the digestive bolus through most of its course, causing retention of water through osmosis leading to softer, easier to pass stool. It has a secondary laxative effect in the colon, where it is fermented by the gut flora, producing metabolites which have osmotic powers and peristalsis-stimulating effects (such as acetate), but also methane associated with flatulence. Lactulose is metabolized in the colon by bacterial flora to short chain fatty acids including lactic acid and acetic acid. These partially dissociate, acidifying the colonic contents (increasing the H+ concentration in the gut).[14] This favors the formation of the nonabsorbable NH+4 from NH3, trapping NH3 in the colon and effectively reducing plasma NH3 concentrations. Lactulose is used in the treatment of chronic constipation in patients of all ages as a long-term treatment. Lactulose is used for chronic idiopathic constipation, i.e. chronic constipation occurring without any identifiable cause. Lactulose may be used to counter the constipating effects of opioids, and in the symptomatic treatment of hemorrhoids as a stool softener.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0015696 Sources: https://www.drugs.com/pro/lactulose.html |
|||
Target ID: GO:0015696 Sources: https://www.drugs.com/pro/lactulose.html |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | CEPHULAC Approved UseFor the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Controlled studies have shown that lactulose solution therapy reduces the blood ammonia levels by 25-50%; this is generally paralleled by an improvement in the patients' mental state and by an improvement in EEG patterns. The clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. An increase in patients' protein tolerance is also frequently observed with lactulose therapy. In the treatment of chronic portal-systemic encephalopathy, Lactulose has been given for over 2 years in controlled studies. Launch Date1976 |
|||
| Primary | CEPHULAC Approved UseFor the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Controlled studies have shown that lactulose solution therapy reduces the blood ammonia levels by 25-50%; this is generally paralleled by an improvement in the patients' mental state and by an improvement in EEG patterns. The clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. An increase in patients' protein tolerance is also frequently observed with lactulose therapy. In the treatment of chronic portal-systemic encephalopathy, Lactulose has been given for over 2 years in controlled studies. Launch Date1976 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| A 45-kDa midgut glycoprotein from Anopheles albimanus mosquito mediates the killing of trypanosomes. | 2002-09 |
|
| Multi-antioxidant supplementation does not prevent an increase in gut permeability after lower torso ischemia and reperfusion in humans. | 2002-07-30 |
|
| Evaluation of hydrogen excretion after lactulose administration as a screening test for causes of irritable bowel syndrome. | 2002-07 |
|
| A randomised controlled trial investigating the effects of dopexamine on gastrointestinal function and organ dysfunction in the critically ill. | 2002-07 |
|
| The relationships between intestinal damage and circulating endotoxins in experimental Trypanosoma brucei brucei infections. | 2002-06 |
|
| Kinetics of urinary recovery of five sugars after orogastric administration in healthy dogs. | 2002-06 |
|
| Production of short-chain fatty acids and gas from various oligosaccharides by gut microbes of carp (Cyprinus carpio L.) in micro-scale batch culture. | 2002-06 |
|
| Gut-associated lymphoid T cell suppression enhances bacterial translocation in alcohol and burn injury. | 2002-06 |
|
| [Hepatic encephalopathy after TIPS--retrospective study]. | 2002-05 |
|
| Comparison of polyethylene glycol 3350 and lactulose for treatment of chronic constipation in children. | 2002-05 |
|
| L-carnitine administration reverses acute mental status changes in a chronic hemodialysis patient with hepatitis C infection. | 2002-05 |
|
| Oligomerization process of the hemolytic lectin CEL-III purified from a sea cucumber, Cucumaria echinata. | 2002-05 |
|
| [Use of lactusan for the correction of microecological intestinal disturbances in children]. | 2002-04-16 |
|
| Mucosal pathology of the upper gastrointestinal tract associated with intensive chemotherapy in children: vitamin A supplements do not prevent lesions. | 2002-04-09 |
|
| Sugar intolerance: origin and mechanisms of symptoms? | 2002-04 |
|
| Alterations in intestinal permeability following the intensified polydrug-chemotherapy IFADIC (ifosfamide, Adriamycin, dacarbazine). | 2002-04 |
|
| The glucose breath test: a diagnostic test for small bowel stricture(s) in Crohn's disease. | 2002-03 |
|
| Nutritional and metabolic consequences of the early Maillard reaction of heat treated milk in the pig. Significance for man. | 2002-02 |
|
| Clinical tests of gastrointestinal permeability that rely on the urinary recovery of enterally administered probes can yield invalid results in critically ill patients. | 2002-02 |
|
| Typhoid, hepatitis E, or typhoid and hepatitis E: the cause of fulminant hepatic failure--a diagnostic dilemma. | 2002-02 |
|
| Home lactulose enema: prevention of hepatic encephalopathy at home. | 2002-01 |
|
| Scintigraphy of the small intestine: a simplified standard for study of transit with reference to normal values. | 2002-01 |
|
| Small intestinal bacterial overgrowth, intestinal permeability, and non-alcoholic steatohepatitis. | 2002-01 |
|
| Liver response to indomethacin-induced intestinal injury. | 2002 |
|
| Efficacy of lactulose plus 13C-acetate breath test in the diagnosis of gastrointestinal motility disorders. | 2002 |
|
| [The response to combined therapy of hepatic encephalopathy in patients with hepatic cirrhosis]. | 2002 |
|
| [Different therapeutic approaches for chronic diffuse liver lesions using ornicetil, lactulose, etimizol and corinfar]. | 2002 |
|
| Effect of lacZY-marking of the 2,4-diacetyl-phloroglucinol producing Pseudomonas fluorescens-strain 5-2/4 on its physiological performance and root colonization ability. | 2002 |
|
| Economic impact of low dose polyethylene glycol 3350 plus electrolytes compared with lactulose in the management of idiopathic constipation in the UK. | 2002 |
|
| Influence of polymeric enteral nutrition supplemented with different doses of glutamine on gut permeability in critically ill patients. | 2001-12-18 |
|
| Lactulose in the prevention of recurrent urinary tract infection. | 2001-12 |
|
| Enzymatic reactions for the determination of sugars in food samples using the differential pH technique. | 2001-12 |
|
| Acute nutritional and intestinal changes after pelvic radiation. | 2001-12 |
|
| Lactose malabsorption and intolerance in the elderly. | 2001-12 |
|
| Intestinal function and metabolism in the early adaptive phase after massive small bowel resection in the rat. | 2001-12 |
|
| Effect of skin pressure by clothing on small bowel transit time. | 2001-11 |
|
| Purification and characterization of two lectins from a toxic moray, Gymnothrax javanicus. | 2001-11 |
|
| A comparative in vitro evaluation of the fermentation properties of prebiotic oligosaccharides. | 2001-11 |
|
| Lactulose-induced pneumatosis intestinalis and pneumoperitoneum. | 2001-11 |
|
| Double blind randomised controlled trial of topical glyceryl trinitrate in anal fissure. | 2001-11 |
|
| Preventing gut leakiness by oats supplementation ameliorates alcohol-induced liver damage in rats. | 2001-11 |
|
| Lactulose may help prevent urinary tract infections. | 2001-10-20 |
|
| Intestinal permeability is increased in a proportion of spouses of patients with Crohn's disease. | 2001-10 |
|
| Importance of increased intestinal permeability after multiple injuries. | 2001-08 |
|
| Intestinal permeability testing using lactulose and rhamnose: a comparison between clinically normal cats and dogs and between dogs of different breeds. | 2001-08 |
|
| In vivo fucosylation of lacto-N-neotetraose and lacto-N-neohexaose by heterologous expression of Helicobacter pylori alpha-1,3 fucosyltransferase in engineered Escherichia coli. | 2001-06 |
|
| Dietary lactulose decreases apparent nitrogen absorption and increases apparent calcium and magnesium absorption in healthy dogs. | 2001-04 |
|
| Small bowel permeability in diagnosis of celiac disease and monitoring of compliance of a gluten-free diet (gut permeability in celiac disease). | 2001 |
|
| A systematic review of the diagnostic accuracy of physical examination for the detection of cirrhosis. | 2001 |
|
| [Disturbance of liver functions and dysbiosis in patients with lipid distress syndrome and its treatment with lactulose preparation "Duphalac" (lactulose)]. | 2001 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/lactulose.html#DA
The usual adult, oral dosage is 2 to 3 tablespoonfuls (30 mL to 45 mL, containing 20 grams to 30 grams of Lactulose) three or four times daily. The dosage may be adjusted every day or two to produce 2 or 3 soft stools daily.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 11:07:29 GMT 2025
by
admin
on
Wed Apr 02 11:07:29 GMT 2025
|
| Record UNII |
9U7D5QH5AE
|
| Record Status |
FAILED
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QA06AD11
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
||
|
LOINC |
74900-2
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
||
|
WHO-ATC |
A06AD61
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
||
|
NCI_THESAURUS |
C68472
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
||
|
WHO-ATC |
A06AD11
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
||
|
NDF-RT |
N0000175811
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
||
|
NCI_THESAURUS |
C29697
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.4
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
||
|
WHO-VATC |
QA06AD61
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
||
|
LOINC |
74899-6
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6218
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY | RxNorm | ||
|
C29148
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY | |||
|
2137
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY | |||
|
DTXSID5045833
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY | |||
|
1536
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY | |||
|
SUB08386MIG
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY | |||
|
3037557
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY | PUBCHEM | ||
|
D007792
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY | |||
|
m6665
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY | Merck Index | ||
|
DB00581
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY | |||
|
757082
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY | |||
|
6359
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY | |||
|
100000091634
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY | |||
|
9U7D5QH5AE
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY | |||
|
225-027-7
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY | |||
|
9U7D5QH5AE
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY | |||
|
LACTULOSE
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY | |||
|
1356803
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY | |||
|
SUB12100MIG
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
ALTERNATIVE | |||
|
CHEMBL296306
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY | |||
|
4618-18-2
Created by
admin on Wed Apr 02 11:07:29 GMT 2025 , Edited by admin on Wed Apr 02 11:07:29 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |